期刊文献+

氢氯噻嗪在小鼠体内的组织分布及药动学研究

Tissue distribution and pharmacokinetics of hydrochlorothiazide in mice by HPLC-MS/MS
下载PDF
导出
摘要 目的建立小鼠血浆及组织中氢氯噻嗪浓度测定的HPLC—MS/MS方法,研究氢氯噻嗪在小鼠体内的组织分布及药动学。方法在血浆样品及组织样品中加入内标布洛芬,分别采用乙醚和乙酸乙酯提取处理,以甲醇-水-氨水(90:10:1)为流动相,用C18柱分离,采用电喷雾电离源(Turbo Ionspray),负离子方式检测,扫描方式为多反应监测(MRM)。以此方法测定72只雄性健康小鼠给予氢氯噻嗪后10个时间点的血浆及组织样品,并采用DAS2.0药动学程序计算主要药动学参数。结果氢氯噻嗪在血浆中线性范围为5.0~1000μg·L^-1,在组织中线性范围为0.05~50.0μg·g^-1,日内、日间RSD均〈15%。小鼠灌胃给予氢氯噻嗪后快速分布在各组织中,其中胃、肠、肝分布最多,心分布最少。结论本法快速、准确、专属、灵敏。氢氯噻嗪灌胃给药后吸收快,消除半衰期长,组织分布广泛。 Objective To establish an LC-MS/MS method for the determination of hydrochlorothiazide in mice plasma and tissue, and to study pharrnacokinetics and tissue distribution of hydrochlorothiazide. Methyls The test drug and internal standard ibuprofen were extracted from plasma samples and tissue samples by ether and ethyl acetate respectively, chromatgraphed on a C18 column. The mobile phase consisted of methanol-wate- ammonia water (90 : 10 : 1 ). Detection was performed on a triple quadrupole tandem mass spectrometer via turbo ionspray source in the negative mode. Hydrochlorothiazide in the plasma and tissue of healthy male mice was deterimined using DAS 2.0 pharmacokinetic program to calculate pharmacokinetic parameters. Results The linear calibration curves were obtained at 5.0- 1000 μg·L^-1 and 0. 05- 50.0 μg·L^-1 in the plasma samples and tissue samples. The intra-and inter-run precisions were lower than 15% in terms of relative standard deviation. After a single dose of the 13 mg·L^-1 hydrochlorothiazide to mice, it was rapidly and extensively distributed to all tissues, especially in the stomach, intestines, and liver. Conehtsion This method is fast, sensitive and accurate. Hydrochlorothiazide is rapidly absorbed with long half life and extensive distribution.
出处 《中南药学》 CAS 2009年第3期179-184,共6页 Central South Pharmacy
关键词 高效液相-串联质谱法 氢氯噻嗪 药动学 组织分布 HPLC-MS/MS hydrochlorothiazide pharmacokinetics tissue distribution
  • 相关文献

参考文献10

二级参考文献23

  • 1刘力生.2004年中国高血压防治指南(实用本)[J].中华心血管病杂志,2004,32(12):1060-1064. 被引量:2620
  • 2许禄,化学计量学方法,1995年
  • 3萧参,中国药学杂志,1993年,28卷,425页
  • 4Luis M,Emesto L.Blood pressure control and benefits of antihypertensive therapy-doesit make a difference which agents we use? Hypertension,2002,38(Part 2):537-542.
  • 5Shah SU,Anjum S,Littler WA.Use of diuretics in cardiovascular disease:(2) hypertension.Postgrad Med J,2004,80:271-276.
  • 6Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group.Diuretic versus alphablocker as first-step antihypertensive therapy:final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).Hypertension,2003,42:239-246.
  • 7Psaty BM,Lumley T,Furberg CD,et al.Health outcomes associated with various antihypertensive therapies used as first-line agents:a network meta-analysis.JAMA,2003,289:2534-2544.
  • 8Wright JM.Choosing a first-line drug in the management of elevated blood pressure:what is the evidence? 1:Thiazide diuretics.CMAJ,2000,163:57-60.
  • 9Leenen FH.ALLHAT:what has it taught us so far? CMAJ,2004,171:719-720.
  • 10Weir MR,Flack JM,Applegate WB.Tolerability,safety,and quality of life and hypertensive therapy:The case for low-dose diuretics.Am J Med,1996,101:83s-92s.

共引文献640

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部